What We Do
We provide an infrastructure that is accelerating research and therapy development, increasing collaboration, improving patient care and helping to support ‘clinical trial readiness’ on an international scale.
TREAT-NMD is internationally recognized for its key role in successfully addressing some of the major issues that face therapeutic development in NMDs. We have a strong track record of advising the scientific and medical community, as well as providing the pharmaceutical industry with essential go-to resources – including education, masterclasses, clinical trial assistance and global data provision – to advance novel treatments for neuromuscular conditions.
Advisory Committee for Therapeutics
Evaluating the therapeutic potential of drugs to optimise their design and development.
Global Registry Network
A federated network of 67 individual, independent, national (or regional) patient registries that collect data on neuromuscular patients from more than 61 countries worldwide.
Giving healthcare providers greater understanding of the diagnosis and management of neuromuscular diseases.
TREAT-NMD contributes to post-marketing surveillance in the neuromuscular field by acting as an independent partner of the Life Sciences Industry and Clinical Research Organisations to facilitate and contribute to international, disease specific PMS systems and processes to fulfil regulatory requirements.
TREAT-NMD have published datasets for 5 diseases: Duchenne Muscular Dystrophy (DMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Myotonic Dystrophy (DM), Spinal Muscular Atrophy (SMA), and Limb Girdle Muscular Dystrophy (LGMD).